Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novo Nordisk A/S (NVO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Novo Nordisk files reports on Form 6‑K that cover financial performance, pipeline progress, governance changes, and material corporate developments.
For a pharmaceutical preparation manufacturer focused on diabetes, obesity, and rare diseases, these filings are a key source of detail on GLP‑1 and semaglutide programs, including Wegovy injection and the Wegovy pill, as well as investigational assets such as CagriSema and cagrilintide. The 6‑K for the first nine months of 2025, for example, outlines sales growth in diabetes and obesity care, rare disease performance, R&D pipeline highlights, and strategic acquisitions in MASH and rare blood disorders.
Investors can also use Novo Nordisk’s filings to monitor capital markets and governance information. Recent 6‑Ks disclose insider transactions in Novo Nordisk B shares by board members and executives, the convening of an Extraordinary General Meeting to elect new board members, and subsequent changes in board leadership and committee composition. Other filings describe agreements with the US Administration on pricing and access for semaglutide medicines in Medicare and Medicaid, and an unsolicited proposal to acquire Metsera, Inc.
On Stock Titan, these filings are updated as they are released on EDGAR. AI‑powered summaries help explain lengthy financial reports and company announcements in plain language, highlighting items such as revenue drivers in diabetes and obesity care, progress in MASH and cardiovascular programs, and the potential impact of pricing agreements. Users can quickly scan Form 6‑K disclosures, identify insider share dealings, and understand how Novo Nordisk’s strategic decisions and R&D investments may shape its long‑term profile in diabetes, obesity, rare disease, and cardiometabolic medicine.
Novo Nordisk A/S is executing a share repurchase programme as part of an overall plan to buy back up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. A specific tranche targets up to DKK 3.8 billion of B shares from 4 February to 4 May 2026.
From 4 February to 20 February 2026, the company repurchased 2,750,000 B shares at an average price of DKK 306.18, for a total of DKK 841,997,435. After these transactions, Novo Nordisk holds 20,139,799 B shares of DKK 0.10 as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk reported headline phase 3 results from the REDEFINE 4 obesity trial comparing once-weekly CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg over 84 weeks in 809 people with obesity and comorbidities.
Using the efficacy estimand assuming full adherence, CagriSema led to 23.0% weight loss at 84 weeks versus 25.5% with tirzepatide. Under the treatment-regimen estimand, weight loss was 20.2% with CagriSema and 23.6% with tirzepatide. The primary endpoint of demonstrating non-inferiority of CagriSema to tirzepatide on weight loss was not achieved.
CagriSema showed a generally safe, well-tolerated profile with mostly mild to moderate gastrointestinal side effects that lessened over time. Novo Nordisk has submitted CagriSema for U.S. approval for weight management based on other pivotal trials, with an FDA decision anticipated by late 2026 and additional REDEFINE 11 and higher-dose CagriSema phase 3 readouts planned through 2027.
Novo Nordisk A/S has called its Annual General Meeting for 26 March 2026 at 14:00 (CET). The meeting will be held as a combined physical and virtual event, allowing shareholders to attend at Bella Center in Copenhagen or participate online by computer or mobile device.
Shareholders are encouraged to submit proxies or votes by correspondence in advance, with practical details provided in the accompanying meeting notice and via a live webcast. All shareholder-elected Board members are up for election, and the Board proposes re-electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and several other members, while nominating Helena Saxon, Jan van de Winkel and Ramona Sequeira as new Board members.
Novo Nordisk is updating investors on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion over a 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 February 2026, Novo Nordisk has repurchased 1,750,000 B shares at an average price of DKK 305.03, for a total of DKK 533,796,640. The company now holds 19,139,799 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports insider transactions by its Chief Financial Officer, Karsten Munk Knudsen, in accordance with market abuse regulation. As Executive Vice President and CFO, he notified two sales of Novo Nordisk B shares.
On 10 February 2026, he sold 26,246 shares at a price of DKK 315.60 per share, for an aggregated amount of DKK 8,283,237.60, executed through JANE STREET NETHERLANDS B.V. He also sold 311 shares at DKK 315.70 per share, for an aggregated amount of DKK 98,182.70, on CBOE EUROPE - DXE PERIODIC (NL). These trades were reported as initial notifications under the rules for persons discharging managerial responsibilities and their closely associated persons.
Novo Nordisk A/S reports an insider share transaction by Executive Vice President for R&D and Chief Scientific Officer Martin Holst Lange. He sold 22,000 Novo Nordisk B shares at DKK 319.80 per share, for a total of DKK 7,035,600.
The transaction, carried out on 9 February 2026 on Nasdaq Copenhagen, was described as a sale of shares to cover tax on shares transferred under the company’s Long Term Incentive programme.
Novo Nordisk A/S is executing a large share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026. Within this, it plans to buy back B shares for up to DKK 3.8 billion from 4 February to 4 May 2026.
As of 6 February 2026, Novo Nordisk has repurchased 750,000 B shares at an average price of DKK 296.40, with a total value of DKK 222,297,903. Incentive plan activity led to a net transfer out of 3,841,954 B shares. The company now holds 18,283,326 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S has reported several insider transactions by board and executive members under its Long Term Incentive programme, as required by market abuse regulations. Shares of Novo Nordisk B (ISIN DK0062498333) were transferred at a price of DKK 0.00 to multiple senior leaders, including Board member Liselotte Sofie Hyveled (1,085 shares) and President and CEO Maziar Mike Doustdar (28,049 shares).
Executives such as David Moore, Emil Kongshøj Larsen, Tania Sabroe, Martin Holst Lange, Thilde Hummel Bøgebjerg, Karsten Munk Knudsen, Kasper Bødker Mejlvang and Ludovic Helfgott also received share transfers ranging from 5,009 to 26,557 shares. In addition, David Moore sold 6,845 shares and Emil Kongshøj Larsen sold 3,645 shares on Nasdaq Copenhagen at DKK 304.72 per share to cover taxes related to these incentive share transfers.
Novo Nordisk A/S is launching its 2026 share repurchase programme of up to DKK 15 billion. As part of this, it has started a new buyback of up to DKK 3.8 billion to run from 4 February 2026 through 4 May 2026.
The company states the purpose is to reduce its share capital and meet obligations from share-based incentive programmes, with a maximum of 400,000,000 B shares of DKK 0.10 in total that can be purchased during the trading period. The programme relies on an existing repurchase authorisation granted at the 27 March 2025 Annual General Meeting and its continuation beyond 26 March 2026 will depend on renewed approval at the 2026 meeting.
The buyback will follow EU Market Abuse Regulation Article 5 and related Safe Harbour Rules, with Nordea Danmark acting as lead manager.
Novo Nordisk presents its 2025 annual report, highlighting continued expansion in obesity and diabetes care, large manufacturing investments and major portfolio moves. Obesity products Saxenda® and Wegovy® generated DKK 82,347 million in 2025, with Wegovy® alone reaching DKK 79,106 million. Ozempic® remained the top product with DKK 127,089 million in sales.
The company is investing tens of billions of DKK in new and expanded production facilities across Denmark, the US, France, China and Brazil to meet GLP‑1 demand. In December 2025 it acquired Akero Therapeutics for USD 4.7 billion plus a USD 0.5 billion contingent value right tied to US approval of efruxifermin for MASH.
Leadership changed as Maziar Mike Doustdar became CEO and the board was reshaped, while a global transformation cut about 9,000 jobs. The report also describes pricing pressure in the US, patent expiries, strong competition in GLP‑1s, and plans to recognise USD 4.2 billion of previously constrained US 340B revenue in early 2026.